Hardwick, MA, United States

Aileron Therapeutics

www.aileronrx.com
Hardwick, MA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Aileron Therapeutics | Date: 2017-08-02

Methods for treating solid tumor, determined to lack a p53 deactivation mutation, in a subject are provided. Also provided are peptidomimetic macrocycles for use in treatment of a solid tumor, determined to lack a p53 deactivation mutation, in a subject.


Patent
Aileron Therapeutics | Date: 2016-08-10

The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.


Patent
Aileron Therapeutics | Date: 2017-08-02

Aqueous pharmaceutical formulations, for parenteral administration, comprising peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof wherein the peptidomimetic macrocycle binds to MDM2 and/or MDMX proteins are disclosed. Also disclosed are methods of treating diseases and disorders using the aqueous pharmaceutical formulations disclosed herein.


Patent
Aileron Therapeutics | Date: 2016-10-24

The present invention provides peptidomimetic macrocycles capable of modulating growth hormone levels and methods of using such macrocycles for the treatment of disease.


Patent
Aileron Therapeutics | Date: 2016-09-28

Provided are crystalline , -disubstituted amino acids and their crystalline salts containing a terminal alkene on one of their side chains, as well as optionally crystalline halogenated and deuterated analogs of the , -disubstituted amino acids and their salts; methods of making these, and methods of using these.


Patent
Aileron Therapeutics | Date: 2016-08-02

The present invention provides peptidomimetic macrocycles capable of modulating growth hormone levels and methods of using such macrocycles for the treatment of disease.


Patent
Aileron Therapeutics | Date: 2017-05-24

The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.


Patent
Aileron Therapeutics | Date: 2016-09-08

The disclosed peptidomimetic macrocycles modulate the activity of MCL-1. Myeloid cell leukemia 1 (MCL-1) is a protein that inhibits cell death. Peptidomimetic macrocycles, pharmaceutical compositions, and methods disclosed herein can be used for the treatment of disease in which MCL-1 is over-expressed, such as cancer. In particular, MCL-1-modulating peptidomimetic macrocycles disclosed herein can be applied in the setting of resistance to BCL-2 family inhibitors, which is often engendered by MCL-1 over-expression or hyper-activation.


Patent
Aileron Therapeutics | Date: 2016-09-02

Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. Also provided here in are methods of using such macrocycles in combination with at least one additional pharmaceutically active agent for treatment of disorders, for example for treatment of cancer.


Patent
Aileron Therapeutics | Date: 2016-04-07

The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.

Loading Aileron Therapeutics collaborators
Loading Aileron Therapeutics collaborators